Putney Receives FDA Approval for Tiletamine-Zolazepam, Generic of Telazol
April 06, 2015
Portland, ME—April 6, 2015—Putney, Inc., a rapidly growing pet pharmaceutical company focused on the development and sale of generic prescription medicines for pets, has received FDA Center for Veterinary Medicine (CVM) approval for its Tiletamine-Zolazepam (tiletamine HCl and zolazepam HCl) injectable, the generic of Telazol. This is Putney's sixth FDA approval in seven months, following closely the FDA approvals for Putney's Carprofen Chewable Tablets (generic of Rimadyl Chewable Tablets), Putney's Desmedetomidine HCl Sterile Injectable Solution (generic of Desdomitor), Putney's Carprofen Sterile Injectable Solution (generic of Rimadyl Injectable), and Putney's Enrofloxacin Antibacterial Injectable Solution (generic of Baytril Antibacterial Injectable Soltuion).
“Putney is the first company to earn FDA approval for the manufacture of generic tiletamine HCl and zolazepam HCl, a very complex, sterile drug. This is another major accomplishment by our R&D team and a great addition to our product portfolio,” says Dr. Anthony Lucas BVMS, PhD, Putney’s Senior Vice President of Scientific and Medical Affairs.
Jean Hoffman, Putney president and CEO, says commercialization of Putney’s recent FDA approvals will accelerate Putney’s revenue growth in 2015 and beyond. “Putney is developing first-to-market, commercially relevant veterinary generics. These are the affordable pet medicines that veterinarians want but have never had access to before,” says Hoffman. She notes that Putney’s impressive 2014 revenue growth of 45% was largely driven by market penetration of existing products.
Putney is planning commercial launch of its Tiletamine-Zolazepam for June 2015.
For the full story and more about Putney visit putneyvet.com.